Can Urolithin A Help Aging Muscles Perform Better?
One of the biggest challenges of aging isn't simply losing muscle mass.
It's losing the ability to maintain strength, endurance, and physical independence.
As we grow older, changes in muscle metabolism, mitochondrial function, physical activity, and recovery can influence how effectively our muscles perform.
That's why researchers have become interested in a compound called Urolithin A.
Urolithin A has attracted attention because preclinical research suggests it can influence mitophagy, the cellular process involved in identifying and removing damaged or unnecessary mitochondria.
Some human trials have also reported improvements in selected muscle-endurance and strength measurements.
But there's an important distinction.
Improving a mitochondrial biomarker is not the same as proving that a supplement prevents age-related muscle loss.
And not every Urolithin A clinical trial has met its primary performance endpoint.
So what have researchers actually discovered?
Let's examine the human evidence, the outcomes measured, and the questions that remain unanswered.
What Is Urolithin A?
Urolithin A is a compound produced through the metabolism of certain dietary polyphenols by microorganisms in the gut.
Foods such as pomegranates, walnuts, and some berries contain ellagitannins and ellagic acid, which can serve as precursors for urolithin production.
However, not everyone produces the same amount of Urolithin A after consuming these foods.
Differences in gut microbiome composition can influence whether and how efficiently an individual produces it.
This variability is one reason researchers have investigated direct Urolithin A supplementation.
The goal is to study its biological effects without depending entirely on an individual's ability to produce it through gut microbial metabolism.
But the presence of a biologically interesting compound doesn't automatically establish a clinical benefit.
That requires controlled human research.
Why Are Researchers Studying Urolithin A for Muscle Health?
Skeletal muscle requires substantial energy to perform everyday activities.
Walking, climbing stairs, lifting objects, and maintaining posture all depend on coordinated muscle contraction and energy metabolism.
Mitochondria play an important role in supporting these activities.
They help convert nutrients into usable energy and participate in cellular signaling and metabolic regulation.
As people age, mitochondrial function can change.
Researchers have also observed alterations in mitochondrial quality-control pathways, which help cells maintain functional mitochondrial populations.
One of those pathways is called mitophagy.
What Is Mitophagy?
Mitophagy is a form of selective autophagy.
It helps cells identify and remove mitochondria that are damaged, dysfunctional, or no longer needed.
This process contributes to mitochondrial quality control.
However, mitophagy is not simply about removing as many mitochondria as possible.
Healthy cells require a balance between mitochondrial removal, maintenance, and replacement.
Researchers are interested in whether influencing this balance could support muscle function during aging.
Preclinical studies suggest that Urolithin A may influence mitophagy-related pathways.
The critical question is whether those effects translate into measurable improvements in humans.
The Early Research: Promising Results in Experimental Models
One influential study published in Nature Medicine in 2016 investigated Urolithin A and mitochondrial function.
Researchers reported that Urolithin A induced mitophagy in experimental models, including Caenorhabditis elegans, a small organism frequently used in aging research.
The study also reported improved muscle function in rodent models.
Study: Ryu and colleagues, 2016
PMID: 27400265
These findings provided an important biological rationale for investigating Urolithin A in humans.
But they were preclinical findings.
Improved mitochondrial quality control in worms or rodents does not prove that supplementation improves muscle performance in older adults.
Human clinical trials are needed to answer that question.
What Do Human Urolithin A Trials Actually Measure?
Researchers have investigated several different outcomes.
Some studies focus on mitochondrial biomarkers, while others examine physical performance.
Common endpoints include muscle endurance, muscle strength, walking distance, ATP production, and blood markers associated with mitochondrial health.
These measurements are related, but they answer different questions.
Muscle strength describes the force a muscle can generate.
Muscle endurance describes the ability to sustain or repeatedly perform muscular activity.
Walking performance reflects a combination of muscle function, cardiovascular fitness, coordination, and other physiological factors.
Mitochondrial biomarkers provide information about biological processes associated with mitochondrial function.
A positive result in one category does not automatically establish improvements in the others.
That distinction becomes especially important when reviewing Urolithin A trials.
Human Trial 1: Urolithin A in Older Adults
One of the most widely discussed Urolithin A studies was published in JAMA Network Open in 2022.
The randomized, double-blind, placebo-controlled trial investigated Urolithin A supplementation in 66 older adults between 65 and 90 years of age.
Participants received either 1,000 mg of Urolithin A daily or placebo for four months.
Researchers examined several outcomes, including walking performance, muscle endurance, and mitochondrial-related measurements.
Study: Liu and colleagues, 2022
PMID: 35050355
What Were the Primary Outcomes?
The study included two primary outcomes:
-
Six-minute walking distance
-
Maximal ATP production in hand muscle
These endpoints were selected to investigate whether Urolithin A could influence physical performance and muscle bioenergetics.
The distinction between primary and secondary outcomes matters because primary outcomes are central to how a clinical trial is designed and interpreted.
Did Urolithin A Improve Walking Distance?
The study did not demonstrate a statistically significant between-group improvement in six-minute walking distance compared with placebo.
That is an important limitation.
The six-minute walk test is a functional assessment used to evaluate walking capacity.
An intervention that improves certain muscle-related biomarkers may still fail to produce a measurable advantage in this broader physical-performance test.
This doesn't necessarily mean the intervention has no biological activity.
It means the trial did not establish a benefit for that primary endpoint.
What Happened to ATP Production?
The study also did not demonstrate a statistically significant between-group improvement in maximal ATP production in the hand muscle.
Again, this was a primary endpoint.
The absence of a significant difference matters when interpreting the overall findings.
Were There Any Positive Results?
Yes.
Researchers reported improvements in selected measures of muscle endurance and changes in certain biomarkers associated with mitochondrial health.
These findings suggested that Urolithin A may influence aspects of muscle physiology that are not fully captured by walking distance or ATP-production measurements.
However, the positive secondary outcomes should be considered alongside the primary outcomes that were not met.
The accurate conclusion is that the trial produced encouraging secondary findings, but it did not demonstrate significant benefits on its two primary endpoints.
Human Trial 2: Urolithin A in Middle-Aged Adults
Another randomized clinical trial published in 2022 investigated Urolithin A supplementation in middle-aged adults.
The study examined 88 participants between approximately 40 and 64 years of age.
Researchers investigated whether supplementation could influence muscle performance and mitochondrial-related biomarkers.
Study: Singh and colleagues, 2022
PMID: 35584623
What Did Researchers Find?
The trial reported improvements in selected measures of muscle strength and changes in biomarkers associated with mitochondrial health.
These findings provided additional human evidence that Urolithin A may influence certain aspects of muscle physiology.
However, the study's primary endpoint involving peak power output did not demonstrate a statistically significant improvement.
This is important because peak power and muscle strength are not identical measurements.
An intervention may influence one aspect of muscular performance without improving another.
Why Does This Matter?
When a trial reports several positive secondary outcomes but does not meet its primary endpoint, the results require careful interpretation.
The findings may identify a promising biological effect.
But they should not be presented as proof that the intervention improves overall muscle performance.
Larger independent studies are needed to determine whether the reported strength-related improvements are reproducible.
What Do These Two Human Trials Tell Us?
The two studies investigated different populations and measured different aspects of muscle performance.
One focused on older adults, while the other investigated middle-aged participants.
Both reported potentially encouraging findings involving selected muscle-related outcomes or mitochondrial biomarkers.
However, both also had important limitations involving primary endpoints.
This creates a more nuanced picture than the claim that Urolithin A has been proven to restore aging muscles.
The available evidence suggests that Urolithin A is biologically active and may influence certain aspects of muscle function.
But the magnitude, consistency, and clinical importance of those effects remain uncertain.
Muscle Endurance Is Not the Same as Muscle Strength
This distinction is especially relevant when evaluating supplement marketing.
Muscle endurance refers to the ability to repeatedly contract or sustain muscular activity over time.
Muscle strength refers to the amount of force a muscle can generate.
Muscle power combines force and speed.
These are different physiological qualities.
A compound that improves muscle endurance does not necessarily improve maximum strength.
Likewise, a change in strength does not automatically translate into better walking performance or reduced risk of falls.
This is why researchers use multiple performance tests.
It is also why claims should accurately reflect the specific endpoints measured.
If a study reports improved muscle endurance, the finding should not automatically be described as improved overall muscle strength or reversed muscle aging.
Do Better Mitochondrial Biomarkers Mean Healthier Muscles?
Mitochondrial biomarkers can provide valuable information about biological responses to an intervention.
Researchers may examine markers associated with mitochondrial gene expression, metabolic pathways, inflammation, or mitochondrial quality control.
But a biomarker is not the same as a clinical outcome.
For example, a change in a mitochondrial-related blood marker does not necessarily prove that muscle tissue has developed more functional mitochondria.
Nor does it automatically demonstrate improvements in walking speed, physical independence, or long-term muscle health.
The strongest evidence would connect biological changes with reproducible improvements in meaningful functional outcomes.
This is why both mechanistic and clinical measurements matter.
Does Urolithin A Actually Increase Mitophagy in Humans?
Preclinical research provides evidence that Urolithin A can influence mitophagy-related pathways.
Human studies have also reported changes in molecular signatures associated with mitochondrial health.
However, demonstrating that a supplement changes a biomarker associated with mitophagy is different from directly proving increased mitophagic activity in human skeletal muscle.
Mitophagy is a dynamic process.
A single measurement of a related protein or gene-expression marker may not reveal the full rate of mitochondrial removal and replacement.
Researchers therefore need careful methods to distinguish changes in pathway activity from direct evidence of altered mitochondrial turnover.
This remains an important area for future human research.
Can Urolithin A Prevent Age-Related Muscle Loss?
Age-related loss of muscle mass, strength, and function is often discussed in relation to sarcopenia.
Sarcopenia can affect mobility, physical independence, and quality of life.
Because mitochondrial dysfunction is one factor associated with muscle aging, Urolithin A has attracted interest as a possible intervention.
However, current human trials do not establish that Urolithin A prevents or treats sarcopenia.
Demonstrating that would require appropriately designed clinical studies examining muscle mass, strength, physical performance, and longer-term outcomes in relevant populations.
It would also be important to compare the intervention with established approaches to maintaining muscle health.
Resistance exercise and adequate nutrition remain important components of healthy muscle aging.
Urolithin A research should be interpreted within that broader context.
What Are the Biggest Limitations of Human Urolithin A Research?
The human evidence is promising, but several limitations remain.
1. Relatively Small Studies
Trials involving dozens of participants can provide useful preliminary evidence.
However, they may not be large enough to reliably detect modest effects or determine which groups benefit most.
2. Short Intervention Periods
Many studies last several weeks or months.
That is useful for investigating short-term biological responses but insufficient to establish long-term protection against age-related muscle decline.
3. Mixed Primary and Secondary Outcomes
Some trials reported positive secondary outcomes while failing to demonstrate significant improvements in their primary endpoints.
These distinctions must be preserved when summarizing the findings.
4. Formulation-Specific Evidence
Clinical trials often investigate a particular Urolithin A preparation.
The findings cannot automatically be generalized to every commercial product containing Urolithin A.
5. Limited Independent Replication
Additional independently conducted trials are needed to confirm whether the reported muscle-related benefits are consistent across populations.
6. Uncertain Long-Term Clinical Benefits
The available trials have not established that Urolithin A prevents disability, reduces falls, treats sarcopenia, or extends human lifespan.
These remain separate clinical questions.
What Would Stronger Human Evidence Look Like?
Future Urolithin A research should focus on outcomes that matter to everyday physical function.
Larger randomized trials could investigate whether supplementation produces consistent improvements in muscle strength, endurance, walking performance, and other validated functional measurements.
Longer intervention periods would help researchers determine whether effects persist.
Studies involving older adults at greater risk of muscle decline could also clarify whether the intervention provides meaningful benefits in clinically relevant populations.
Researchers should continue investigating mitochondrial mechanisms, but ideally alongside direct muscle-function measurements.
Independent replication would be particularly valuable.
The goal should be to determine not only whether Urolithin A influences mitochondrial biology, but whether those changes reliably translate into better physical function.
How Should You Evaluate a Urolithin A Supplement?
If you're exploring Urolithin A products, start with the formulation and the human evidence.
Look at the amount of Urolithin A per serving, the complete ingredient list, recommended use, and available quality information.
Compare the product with the preparations and doses investigated in published clinical trials.
A commercial product containing Urolithin A should not automatically be assumed to reproduce the findings of studies using a different formulation.
It is also important to distinguish between claims about mitochondrial biomarkers and claims about physical performance.
The research should help you evaluate the product, not be used to imply benefits that haven't been demonstrated.
Why Urolithin A Research Matters for Healthy Aging
Muscle health is central to maintaining physical independence as we age.
Strength, endurance, mobility, and the ability to perform everyday activities all contribute to healthy aging.
Urolithin A is scientifically interesting because it connects mitochondrial quality-control research with measurable aspects of human muscle performance.
Preclinical findings established a biological rationale for investigating the compound.
Human trials have begun testing whether that rationale translates into functional benefits.
The results so far are encouraging in some areas and uncertain in others.
That combination is common in emerging longevity research.
The important next step is not to assume the hypothesis has been proven.
It is to test the most promising findings more rigorously.
The Bottom Line
Urolithin A has become an important compound in muscle-aging research because of its potential influence on mitochondrial quality-control pathways.
Preclinical studies suggest that it can affect mitophagy-related processes.
Human trials have reported improvements in selected muscle-endurance, strength, and mitochondrial-related outcomes.
However, important primary endpoints in two frequently cited randomized trials were not significantly improved compared with placebo.
That means the evidence does not currently establish that Urolithin A reverses muscle aging, prevents sarcopenia, or reliably improves every aspect of physical performance.
The most accurate conclusion is that Urolithin A has shown promising but mixed results in human muscle research, and larger independent trials are needed to establish its clinical value.
The biology is interesting.
The human evidence is developing.
And the most important questions are still being tested.
Explore the Muscle Research
Want to understand how mitochondrial function, mitophagy, and muscle performance change with age?
Explore Aeternum's educational research on Urolithin A, mitochondrial quality control, muscle endurance, and healthy aging.
Learn what human clinical trials actually measured, which outcomes improved, and where uncertainty remains.
Explore Aeternum's Muscle Research
For readers interested in Urolithin A supplementation, you can also review Aeternum's product information, including formulation details, serving amounts, and available quality information.
Explore Urolithin A Product Information
Start with the research and evaluate the evidence before drawing conclusions about potential benefits.
Research Featured in This Article
Ryu D, et al. (2016).
Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents.
Nature Medicine.
PMID: 27400265
Read the preclinical study on PubMed
This influential study established a biological rationale for investigating Urolithin A and mitochondrial quality control. Its lifespan findings came from experimental organisms, not humans.
Liu S, et al. (2022).
Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial.
JAMA Network Open.
PMID: 35050355
Read the randomized trial on PubMed
This trial investigated 66 older adults receiving Urolithin A or placebo for four months. It reported improvements in selected muscle-endurance and mitochondrial-related outcomes, while the primary walking-distance and ATP-production endpoints were not significantly improved between groups.
Singh A, et al. (2022).
Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults.
Cell Reports Medicine.
PMID: 35584623